FineMark National Bank & Trust’s Neurocrine Biosciences NBIX Stock Holding History

FineMark National Bank & Trust’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-28	Closed	-$1K	–	1387
2016 Q2	$1K	Hold	28	–	–	﹤0.01%	1310
2016 Q1	$1K	Hold	28	–	–	﹤0.01%	1236
2015 Q4	$2K	Buy	+28	New	+$1.42K	﹤0.01%	1189
2015 Q3	–	Sell	-19	Closed	-$1K	–	1564
2015 Q2	$1K	Hold	19	–	–	﹤0.01%	1355
2015 Q1	$1K	Buy	+19	New	+$680	﹤0.01%	1338

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FineMark National Bank & Trust's NBIX Position: Q3 2016 in Review

FineMark National Bank & Trust sold out of Neurocrine Biosciences (NBIX) in Q3 2016, closing a stake of 28 shares — an estimated $1K sold.

FineMark National Bank & Trust first reported a position in NBIX in Q1 2015 and held it in 5 quarters. The position peaked at $2K in Q4 2015. 245 funds tracked by Wall St. Rank hold NBIX as of Q3 2016.

FineMark National Bank & Trust reported no remaining Neurocrine Biosciences position as of Q3 2016 after selling out during the quarter.
FineMark National Bank & Trust sold 28 Neurocrine Biosciences shares in Q3 2016, an estimated $1K.
FineMark National Bank & Trust first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 5 quarters.
FineMark National Bank & Trust's Neurocrine Biosciences position peaked at $2K in Q4 2015.
245 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2016.

Based on FineMark National Bank & Trust's 13F filing for Q3 2016, filed 10 Nov 2016.